

July 28, 2022

Sodium Chloride Injection, USP
Supply Update

Dear Valued Customer,

Fresenius Kabi Canada regrets to advise that due to shipping delays, we will be encountering a supply interruption on our **Sodium Chloride Injection, USP 4mEq/mL Maxivial® 200 mL** effective **August 1, 2022** until **August 21, 2022**. Once available, this product will remain on allocation. Contract customers will be allocated **100% of historical monthly demand**.

We will also be extending our backorder on **Sodium Chloride Injection, USP 4 mEq/mL SD Vial 30 mL** until **August 15, 2022**. Once available, this product will be placed on allocation. Contract customers will be allocated **100% of historical monthly demand**.

DIN	Fresenius Kabi Product Code	MDP Product Code	McKesson Product Code	Product Description	Estimated Stockout Date*	Estimated Availability Date
02139510	C918930	975916	158460	Sodium Chloride Injection, USP 4 mEq/mL SD Vial 30 mL	Jul. 1, 2022	Aug. 15, 2022 (previously Jul. 31, 2022)
02139510	C88B2	922869	594234	Sodium Chloride Injection, USP 4mEq/mL Maxivial® 200 mL	Aug. 1, 2022	Aug. 21, 2022

*Please note that the stockout date may vary by region, please check your local distribution centre for availability.

Please note effective **August 1, 2022**, allocations for our **Sodium Chloride Injection, USP 4mEq/mL Maxivial® 100mL** will be reduced to cover only 100mL demand. Contract customers will be allocated **100% of historical monthly demand**.

DIN	Fresenius Kabi Product Code	MDP Product Code	McKesson Product Code	Product Description	Supply Status
02139510	C88B1	922857	594309	Sodium Chloride Injection, USP 4mEq/mL Maxivial® 100 mL	Effective Aug. 1, 2022, allocations reduced to cover only 100% of 100 mL demand.

We recognize the difficulties and inconvenience that you may encounter as a result of our supply interruption, and we thank you for your patience and understanding in this matter.

If you have any questions or concerns, please do not hesitate to contact your sales representative.

Sincerely,



George Shamsoun
 Associate Director – Marketing, IV Drugs
george.shamsoun@fresenius-kabi.com